This company is no longer active
Magenta Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Magenta Therapeutics has a total shareholder equity of $74.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $78.6M and $4.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$77.59m |
| Equity | US$74.60m |
| Total liabilities | US$4.03m |
| Total assets | US$78.64m |
Recent financial health updates
Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?
Dec 10
Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?
Jul 13Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation
Apr 12Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation
Dec 16Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans
Aug 26Recent updates
Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?
Dec 10Magenta Therapeutics downgraded to neutral at Goldman Sachs on clarity over candidate
Aug 25Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Invest In Growth?
Jul 13Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation
Apr 12Here's Why We're Not Too Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation
Dec 16Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans
Aug 26Magenta Therapeutics (MGTA) EHA Investor Presentations - Slideshow
Jun 18We're Not Very Worried About Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Rate
May 09Magenta Therapeutics EPS beats by $0.04
May 06What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?
Mar 17Magenta Therapeutics (NASDAQ:MGTA) Is In A Good Position To Deliver On Growth Plans
Jan 23
Magenta Therapeutics announces expected 2021 highlights milestones
Jan 11What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares?
Dec 01Financial Position Analysis
Short Term Liabilities: MGTA's short term assets ($78.6M) exceed its short term liabilities ($4.0M).
Long Term Liabilities: MGTA has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: MGTA is debt free.
Reducing Debt: MGTA has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MGTA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MGTA has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 11.6% each year.